Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses

P. B. Jahrling, J. Geisbert, J. R. Swearengen, G. P. Jaax, T. Lewis, J. W. Huggins, J. J. Schmidt, James LeDuc, C. J. Peters

Research output: Contribution to journalArticle

154 Citations (Scopus)

Abstract

A commercially available immunoglobulin G (IgG) from horses, hyperimmunized to Ebola virus, was evaluated for its ability to protect cynomolgus monkeys against disease following i.m. inoculation with 1 000 PFU Ebola virus (Zaire '95 strain). Six monkeys were treated immediately after infection by i.m. injection of 6.0 ml IgG; these animals developed passive ELISA titers of 1:160 to 1:320 to Ebola, two days after inoculation. However, the beneficial effects of IgG treatment were limited to a delay in onset of viremia and clinical signs, in comparison with untreated controls. The six IgG recipients had no detectable viremia day 5, in contrast with three virus infected controls whose viremias exceeded 7.0 log10 PFU/ml that day. The controls died on days 6, 6, and 7, while two IgG recipients died day 7 and the remaining 4 died day 8, all with high viremias. These results document that passively acquired antibody can have a beneficial effect in reducing the viral burden in Ebola-infected primates; however, effective treatment of human patients may require antibodies with higher specific activities and more favorable pharmacokinetic properties than the presently available equine IgG.

Original languageEnglish (US)
Pages (from-to)135-140
Number of pages6
JournalArchives of Virology, Supplement
Volume1996
Issue number11
StatePublished - 1996
Externally publishedYes

Fingerprint

Ebolavirus
Passive Immunization
Macaca fascicularis
Horses
Immunoglobulins
Immunoglobulin G
Viremia
Monkey Diseases
Antibodies
Viral Load
Primates
Haplorhini
Pharmacokinetics
Enzyme-Linked Immunosorbent Assay
Viruses
Injections
Therapeutics
Infection

ASJC Scopus subject areas

  • Immunology and Microbiology(all)

Cite this

Jahrling, P. B., Geisbert, J., Swearengen, J. R., Jaax, G. P., Lewis, T., Huggins, J. W., ... Peters, C. J. (1996). Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. Archives of Virology, Supplement, 1996(11), 135-140.

Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. / Jahrling, P. B.; Geisbert, J.; Swearengen, J. R.; Jaax, G. P.; Lewis, T.; Huggins, J. W.; Schmidt, J. J.; LeDuc, James; Peters, C. J.

In: Archives of Virology, Supplement, Vol. 1996, No. 11, 1996, p. 135-140.

Research output: Contribution to journalArticle

Jahrling, PB, Geisbert, J, Swearengen, JR, Jaax, GP, Lewis, T, Huggins, JW, Schmidt, JJ, LeDuc, J & Peters, CJ 1996, 'Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses', Archives of Virology, Supplement, vol. 1996, no. 11, pp. 135-140.
Jahrling PB, Geisbert J, Swearengen JR, Jaax GP, Lewis T, Huggins JW et al. Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. Archives of Virology, Supplement. 1996;1996(11):135-140.
Jahrling, P. B. ; Geisbert, J. ; Swearengen, J. R. ; Jaax, G. P. ; Lewis, T. ; Huggins, J. W. ; Schmidt, J. J. ; LeDuc, James ; Peters, C. J. / Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. In: Archives of Virology, Supplement. 1996 ; Vol. 1996, No. 11. pp. 135-140.
@article{f1641c5fc10f4c84b82e00b1e9ed9bd0,
title = "Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses",
abstract = "A commercially available immunoglobulin G (IgG) from horses, hyperimmunized to Ebola virus, was evaluated for its ability to protect cynomolgus monkeys against disease following i.m. inoculation with 1 000 PFU Ebola virus (Zaire '95 strain). Six monkeys were treated immediately after infection by i.m. injection of 6.0 ml IgG; these animals developed passive ELISA titers of 1:160 to 1:320 to Ebola, two days after inoculation. However, the beneficial effects of IgG treatment were limited to a delay in onset of viremia and clinical signs, in comparison with untreated controls. The six IgG recipients had no detectable viremia day 5, in contrast with three virus infected controls whose viremias exceeded 7.0 log10 PFU/ml that day. The controls died on days 6, 6, and 7, while two IgG recipients died day 7 and the remaining 4 died day 8, all with high viremias. These results document that passively acquired antibody can have a beneficial effect in reducing the viral burden in Ebola-infected primates; however, effective treatment of human patients may require antibodies with higher specific activities and more favorable pharmacokinetic properties than the presently available equine IgG.",
author = "Jahrling, {P. B.} and J. Geisbert and Swearengen, {J. R.} and Jaax, {G. P.} and T. Lewis and Huggins, {J. W.} and Schmidt, {J. J.} and James LeDuc and Peters, {C. J.}",
year = "1996",
language = "English (US)",
volume = "1996",
pages = "135--140",
journal = "Archives of virology. Supplementum.",
issn = "0939-1983",
publisher = "Springer Verlag",
number = "11",

}

TY - JOUR

T1 - Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses

AU - Jahrling, P. B.

AU - Geisbert, J.

AU - Swearengen, J. R.

AU - Jaax, G. P.

AU - Lewis, T.

AU - Huggins, J. W.

AU - Schmidt, J. J.

AU - LeDuc, James

AU - Peters, C. J.

PY - 1996

Y1 - 1996

N2 - A commercially available immunoglobulin G (IgG) from horses, hyperimmunized to Ebola virus, was evaluated for its ability to protect cynomolgus monkeys against disease following i.m. inoculation with 1 000 PFU Ebola virus (Zaire '95 strain). Six monkeys were treated immediately after infection by i.m. injection of 6.0 ml IgG; these animals developed passive ELISA titers of 1:160 to 1:320 to Ebola, two days after inoculation. However, the beneficial effects of IgG treatment were limited to a delay in onset of viremia and clinical signs, in comparison with untreated controls. The six IgG recipients had no detectable viremia day 5, in contrast with three virus infected controls whose viremias exceeded 7.0 log10 PFU/ml that day. The controls died on days 6, 6, and 7, while two IgG recipients died day 7 and the remaining 4 died day 8, all with high viremias. These results document that passively acquired antibody can have a beneficial effect in reducing the viral burden in Ebola-infected primates; however, effective treatment of human patients may require antibodies with higher specific activities and more favorable pharmacokinetic properties than the presently available equine IgG.

AB - A commercially available immunoglobulin G (IgG) from horses, hyperimmunized to Ebola virus, was evaluated for its ability to protect cynomolgus monkeys against disease following i.m. inoculation with 1 000 PFU Ebola virus (Zaire '95 strain). Six monkeys were treated immediately after infection by i.m. injection of 6.0 ml IgG; these animals developed passive ELISA titers of 1:160 to 1:320 to Ebola, two days after inoculation. However, the beneficial effects of IgG treatment were limited to a delay in onset of viremia and clinical signs, in comparison with untreated controls. The six IgG recipients had no detectable viremia day 5, in contrast with three virus infected controls whose viremias exceeded 7.0 log10 PFU/ml that day. The controls died on days 6, 6, and 7, while two IgG recipients died day 7 and the remaining 4 died day 8, all with high viremias. These results document that passively acquired antibody can have a beneficial effect in reducing the viral burden in Ebola-infected primates; however, effective treatment of human patients may require antibodies with higher specific activities and more favorable pharmacokinetic properties than the presently available equine IgG.

UR - http://www.scopus.com/inward/record.url?scp=0029687228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029687228&partnerID=8YFLogxK

M3 - Article

C2 - 8800795

AN - SCOPUS:0029687228

VL - 1996

SP - 135

EP - 140

JO - Archives of virology. Supplementum.

JF - Archives of virology. Supplementum.

SN - 0939-1983

IS - 11

ER -